CDXS Stock Analysis — CODEXIS INC (Healthcare >> Biotechnology)
CDXS FAQ
What is CDXS's P/E ratio?
CODEXIS INC (CDXS) currently trades at a P/E ratio of 16.58.
What is CDXS's ROE?
CODEXIS INC reports a Return on Equity (ROE) of -73.99%.
What is CDXS's dividend yield?
CODEXIS INC offers a dividend yield of 0.00%.
What is CDXS's Quality Score?
Our AI rates CDXS's overall financial quality at 62 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CDXS?
Our AI Timing Score for CDXS is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CDXS belong to?
CODEXIS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
CDXS AI Analysis Summary
Our AI summary for CDXS: CODEXIS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 16.58, ROE of -73.99%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 1.40
Price
-0.08
(-5.41%)
Day Change
|
|
|---|
CDXS, the overall quality is ok ( Quality = 62) and the timing to buy is ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Net profit margin is relatively low.
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 89 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.40 |
| PBV / Sector |
3.68 / 5.20
|
| Earning Per Share | -0.28 |
| PE / Sector |
16.58 / 19.97
|
| PEG or PE/Growth / Sector |
0.92 / 1.22
|
| Average 1M Daily Value |
2.32 M
GREAT
|
| Average 1W Daily Value |
2.52 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
43% |
| Ability to Make Profit |
|
64% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-01 07:59:37 |
| Symbol | CDXS |
| Name | CODEXIS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 107.56 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 159.19 / 9,903.94 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 200 Penobscot Drive, Redwood City, CA, United States, 94063
Phone: 650 421 8100
Website: https://www.codexis.com
Employees: 146
Sector: Healthcare >> Biotechnology
Description: Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap
Google